论文部分内容阅读
目的:探讨普米克都保联合沙丁胺醇对咳嗽变异性哮喘(CVA)患儿的疗效分析。方法:选取100例CVA患者,沙丁胺醇组(48例)给予沙丁胺醇联合用药组(52例)给予沙丁胺醇和普米克都保,观察并记录两组患者治疗后的疗效,咳嗽缓解及消失时间,治疗前后的用力肺活量(FVC),第1秒用力呼气容积(FEV1)、呼气峰流速(PEF)及最大呼气中段流速(MMEF)等肺功能指标及随访1个月期间的不良反应,评价普米克都保联合沙丁胺醇对咳嗽变异性哮喘的疗效。结果:治疗后联合用药组有效率明显高于沙丁胺醇组(P<0.05),联合用药组中有92.3%患者,沙丁胺醇组有72.9%患者咳嗽症状在2周内消失,治疗后联合用药组咳嗽缓解时间和消失时间明显短于沙丁胺醇组(P<0.05)。治疗前后,两组在FVC,FEVl,PEF上相比,差异没有统计学意义(P>0.05),治疗前,两组MMEF水平均明显低于体检健康者(P<0.05),其他肺功能指标与体检健康者相比,无统计学差异(P>0.05)。治疗后联合用药组MMEF明显高于治疗前,且高于沙丁胺醇组(P<0.05)。沙丁胺醇组治疗前后MMEF未出现明显变化(P>0.05)。随访1个月期间,两组不良反应率相比,差异没有统计学意义(P>0.05)。结论:普米克都保联合沙丁胺醇能对CVA具有较好的治疗作用,能缩短咳嗽症状消失时间,改善患儿肺功能,值得临床推广使用。
Objective: To investigate the curative effect of Pulmicort-bolus combined salbutamol on children with cough-variant asthma (CVA). Methods: 100 patients with CVA were selected. Salbutamol group (n = 48) was treated with salbutamol combined with salbutamol (52 patients) and salmeterol and metoprolol. The curative effect, cough relief and disappearance time were observed and recorded before and after treatment (FVC), forced expiratory volume in 1 second (FEV 1), peak expiratory flow (PEF) and maximal expiratory flow velocity (MMEF), and other adverse reactions during follow-up of 1 month, Efficacy of metostatin plus salbutamol on cough variant asthma. Results: The effective rate of combination group was significantly higher than that of salbutamol group (92.3%) in combination group and 72.9% (42.9%) of salbutamol group disappeared in 2 weeks after treatment, and the cough in combination group was relieved after treatment Time and disappearance time was significantly shorter than salbutamol group (P <0.05). Before and after treatment, there was no significant difference between the two groups in FVC, FEV1 and PEF (P> 0.05). Before treatment, the levels of MMEF in both groups were significantly lower than those in healthy subjects (P <0.05) Compared with healthy people, there was no significant difference (P> 0.05). After treatment, the combined treatment group MMEF was significantly higher than before treatment, and higher than salbutamol group (P <0.05). There was no significant change in MMEF before and after salbutamol treatment (P> 0.05). There was no significant difference in adverse reactions between the two groups during follow-up of 1 month (P> 0.05). Conclusions: Pulmicort and albuterol combined with salbutamol can have a good therapeutic effect on CVA, which can shorten the disappearance time of cough symptoms and improve the pulmonary function in children, which is worthy of clinical promotion.